New Drug Firm Xinji Pharma Files for Hong Kong IPO

Stock News12-24

Guangzhou Xinji Pharmaceuticals Co., Ltd. ("Xinji Pharma") has submitted its listing application to the Hong Kong Stock Exchange's main board, with Haitong International as its sole sponsor.

Founded in 2007 and headquartered in Guangzhou, China, Xinji Pharma is a clinical-stage biotech company focused on innovative drug development. The company has established two proprietary technology platforms: (i) a soluble microneedle patch platform and (ii) a nasal inhalation formulation platform.

Xinji Pharma's lead product is a dexmedetomidine hydrochloride microneedle patch developed for preoperative sedation in both pediatric and adult patients. As of December 18, 2025, the pediatric formulation has entered Phase IIa clinical trials in China, while the adult version has received NMPA approval for Phase II trials expected to begin in Q1 2026.

The company's second core product, XJN010, is a nasal inhalation formulation designed for on-demand treatment of "off" episodes in Parkinson's disease patients. XJN010 has progressed to Phase II clinical trials in China as of December 18, 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1163321221?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-24 15:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163321221","market":"nz","top_or_hot":-1,"title":"New Drug Firm Xinji Pharma Files for Hong Kong IPO","media":"Stock News","content":"<p>Guangzhou Xinji Pharmaceuticals Co., Ltd. (\"Xinji Pharma\") has submitted its listing application to the Hong Kong Stock Exchange's main board, with Haitong International as its sole sponsor.</p>\n<p>Founded in 2007 and headquartered in Guangzhou, China, Xinji Pharma is a clinical-stage biotech company focused on innovative drug development. The company has established two proprietary technology platforms: (i) a soluble microneedle patch platform and (ii) a nasal inhalation formulation platform.</p>\n<p>Xinji Pharma's lead product is a dexmedetomidine hydrochloride microneedle patch developed for preoperative sedation in both pediatric and adult patients. As of December 18, 2025, the pediatric formulation has entered Phase IIa clinical trials in China, while the adult version has received NMPA approval for Phase II trials expected to begin in Q1 2026.</p>\n<p>The company's second core product, XJN010, is a nasal inhalation formulation designed for on-demand treatment of \"off\" episodes in Parkinson's disease patients. XJN010 has progressed to Phase II clinical trials in China as of December 18, 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New Drug Firm Xinji Pharma Files for Hong Kong IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew Drug Firm Xinji Pharma Files for Hong Kong IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-24 15:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Guangzhou Xinji Pharmaceuticals Co., Ltd. (\"Xinji Pharma\") has submitted its listing application to the Hong Kong Stock Exchange's main board, with Haitong International as its sole sponsor.</p>\n<p>Founded in 2007 and headquartered in Guangzhou, China, Xinji Pharma is a clinical-stage biotech company focused on innovative drug development. The company has established two proprietary technology platforms: (i) a soluble microneedle patch platform and (ii) a nasal inhalation formulation platform.</p>\n<p>Xinji Pharma's lead product is a dexmedetomidine hydrochloride microneedle patch developed for preoperative sedation in both pediatric and adult patients. As of December 18, 2025, the pediatric formulation has entered Phase IIa clinical trials in China, while the adult version has received NMPA approval for Phase II trials expected to begin in Q1 2026.</p>\n<p>The company's second core product, XJN010, is a nasal inhalation formulation designed for on-demand treatment of \"off\" episodes in Parkinson's disease patients. XJN010 has progressed to Phase II clinical trials in China as of December 18, 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09939","symbol_name":"开拓药业-B","start_time":0,"source_url":"","article_id":"1163321221","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163321221","pubTimestamp":1766560775,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Guangzhou Xinji Pharmaceuticals Co., Ltd. (\"Xinji Pharma\") has submitted its listing application to the Hong Kong Stock Exchange's main board, with Haitong International as its sole sponsor. Founded...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","09939":"开拓药业-B","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"新药公司新基制药申请香港IPO","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"09939":1,"HEXmain":1},"content_text":"Guangzhou Xinji Pharmaceuticals Co., Ltd. (\"Xinji Pharma\") has submitted its listing application to the Hong Kong Stock Exchange's main board, with Haitong International as its sole sponsor.\nFounded in 2007 and headquartered in Guangzhou, China, Xinji Pharma is a clinical-stage biotech company focused on innovative drug development. The company has established two proprietary technology platforms: (i) a soluble microneedle patch platform and (ii) a nasal inhalation formulation platform.\nXinji Pharma's lead product is a dexmedetomidine hydrochloride microneedle patch developed for preoperative sedation in both pediatric and adult patients. As of December 18, 2025, the pediatric formulation has entered Phase IIa clinical trials in China, while the adult version has received NMPA approval for Phase II trials expected to begin in Q1 2026.\nThe company's second core product, XJN010, is a nasal inhalation formulation designed for on-demand treatment of \"off\" episodes in Parkinson's disease patients. XJN010 has progressed to Phase II clinical trials in China as of December 18, 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1163321221","isCrawlerRequest":true}